Coffee consumption and risk of cancers: a meta-analysis of cohort studies

Xiaofeng Yu, Zhijun Bao, Jian Zou*, Jie Dong

Abstract

Background: Coffee consumption has been shown to be associated with cancer of various sites in epidemiological studies. However, there is no comprehensive overview of the substantial body of epidemiologic evidence.

Methods: We searched MEDLINE, EMBASE, Science Citation Index Expanded and bibliographies of retrieved articles. Prospective cohort studies were included if they reported relative risks (RRs) and corresponding 95% confidence intervals (CIs) of various cancers with respect to frequency of coffee intake. We did random-effects meta-analyses and meta-regressions of study-specific incremental estimates to determine the risk of cancer associated with 1 cup/day increment of coffee consumption.

Results: 59 studies, consisting of 40 independent cohorts, met the inclusion criteria. Compared with individuals who did not or seldom drink coffee per day, the pooled RR of cancer was 0.87 (95% CI, 0.82-0.92) for regular coffee drinkers, 0.89 (0.84-0.93) for low to moderate coffee drinkers, and 0.82 (0.74-0.89) for high drinkers. Overall, an increase in consumption of 1 cup of coffee per day was associated with a 3% reduced risk of cancers (RR, 0.97; 95% CI, 0.96-0.98). In subgroup analyses, we noted that, coffee drinking was associated with a reduced risk of bladder, breast, buccal and pharyngeal, colorectal, endometrial, esophageal, hepatocellular, leukemic, pancreatic, and prostate cancers.

Conclusions: Findings from this meta-analysis suggest that coffee consumption may reduce the total cancer incidence and it also has an inverse association with some type of cancers.

Background

Coffee is one of the most widely consumed beverages in the world, with a yearly world average consumption of 1.1 kg per capita, which reaches 4.5 kg in industrialized countries[1]. More recently, coffee consumption has been associated with reductions in the risk of several chronic diseases, including type 2 diabetes mellitus, Parkinson’s disease and hepatocellular disease[2-4]. Among them, the relationship between coffee drinking and cancer risk holds great interest.

Roasted coffee is a complex mixture of more than a thousand chemicals. Many constituents in it could potentially alter cancer risk through several biological mechanisms. Coffee is the major source of caffeine which has been reported to both stimulate and suppress tumors, depending upon the species and the phase of administration[5]. There are two specific diterpenes in coffee, cafestol and kahweal, which produce biological effects compatible with anticarcinogenic properties, including the induction of phase II enzymes involved in carcinogen detoxification,[6] specific inhibition of the activity of phase I enzyme responsible for carcinogen activation and stimulation of intracellular antioxidant defense mechanisms[7]. Polyphenols are an important ingredient in coffee, such as lignan phytoestrogens and flavonoids and polyphenols are found to exhibit anticarcinogenic properties in several studies[8]. Caffeic acid has the ability to inhibit DNA methylation in cultured human cancer cells and is associated with inactivation of various pathways involved in the tumorigenic process, including cell cycle regulation, inflammatory and stress response and apoptosis[9]. Coffee is also a major source of the chlorogenic acid that contributes to its antioxidant effect. Intake of chlorogenic acid has been shown to reduce glucose concentrations in rats and intake of

* Correspondence: apollozou@hotmail.com
Department of Gastroenterology, Huadong Hospital, Fudan University, Shanghai 200040, PR China
quinines, degradation products of chlorogenic acid, increases insulin sensitivity[10]. Chronic hyperinsulinemia and insulin resistance are confirmed markers of high risk for some cancer sites[11].

Over the last 4 decades, a number of epidemiologic studies (over 500 papers) have estimated the associations between coffee consumption and cancer occurrence at various sites. However, their results were inconsistent. In 2007, the World Cancer Research Fund (WCRF) conducted a comprehensive analysis of diet and cancer, using a more standardized approach to review the evidence. This report addressed the significant relationships between coffee and risk of pancreatic and kidney cancer[5]. In fact, epidemiologic studies have been published relating coffee intake to cancers of 11 different organ sites. Data from case-control studies may be subject to recall bias with respect to coffee consumption and selection bias with respect to the control group. Additional prospective cohort studies excluding those biases would be more useful to see coffee-cancer associations. We therefore systematically reviewed and performed a meta-analysis of prospective cohort studies to quantitatively assess the association between coffee intake and cancer risk in human. Because of the high consumption of coffee, even small effects on cancer occurrence in persons could have a large impact on public health.

Methods

Literature search

We searched the electronic databases MEDLINE (1966 to March, 2010), EMBASE (1985 to March, 2010), and Science Citation Index Expanded (1945 to March, 2010), using the Medical Subject Heading (MeSH) term coffee combined with cancer or neoplasm or carcinoma. Furthermore, we reviewed reference lists of retrieved articles to search for more studies. Only those that were published as full-length articles and in English were considered.

Inclusion and exclusion criteria

For inclusion, studies had to fulfill the following criteria: have a prospective cohort design; report relative risks or hazard ratios and their corresponding 95% CIs (or data to calculate them) of cancer relating to every category of coffee intake; and provide the frequency of coffee consumption. Studies were excluded if: case-control design was used; mixed beverage was reported, in which the effect of coffee could not be separated; only surrogate nutrients of coffee were reported; no categories of coffee intake were reported that could not allow for adequate classification of intake. If multiple published reports from a same study cohort were available, we included only the one with the most detailed information for both outcome and coffee consumption.

Data extraction

Data were extracted independently by two investigators (Yu and Bao) according to the meta-analysis of observation studies in epidemiology (MOOSE) guidelines,[12] and discrepancies were resolved by discussion with a third investigator (Zou). For each study, the following information was extracted: first author’s last name; year of publication; country of origin; follow-up period; number of subjects and cases; age at baseline; cancer sites; category amounts of coffee intake; outcome assessment; relative risks or hazard ratios of cancer and corresponding 95% CIs for every category of coffee intake; and covariates adjusted in the statistical analysis.

Statistical analysis

The measures of interest were the RR and the corresponding 95% CIs for the included cohort studies. When RRs were not available in the published article, they were computed from the exposure distributions. Because various studies used different measurement units for coffee consumption, we converted these into cups per day as a standard measure. If coffee consumption was indicated in milliliters, we assumed 125 mL as approximately equivalent to 1 cup.

We computed the summary RR for coffee drinkers versus nondrinkers and for different levels of consumption by giving each study-specific RR a weight that was proportional to its precision (ie, the inverse of the variance derived, when necessary, from the reported 95% CIs). To estimate the summary RR for various levels of coffee consumption, we first calculated the study-specific estimate separately for low to moderate consumption and high consumption. For various cancer sites, we performed stratified analysis on cancer types which had more than two cohorts.

Statistical heterogeneity among studies was estimated using Q and I^2 statistics. For the Q statistic, heterogeneity was considered present for P < 0.1. We pooled the study-specific estimates using both the fixed effect model and the random effect model proposed by DerSimonian and Laird; when a significant heterogeneity was found, the random effect model results were presented. A sensitivity analysis was also conducted, in which 1 study at a time was removed and the others analyzed to estimate whether the results could have been affected markedly by a single study.

For dose-response analysis, we used the method proposed by Greenland and Longnecker[13] to estimate study-specific slopes from the correlated natural logarithm of the RR across categories of coffee consumption, assigning to each class the dose corresponding to the midpoint of upper and lower boundaries. The highest, open-ended category was assumed to have the same amplitude of consumption as the preceding category.
The estimated RR of various cancer sites for coffee drinkers vs non/lowest drinkers was 0.87 (95% CI, 0.82-0.92). There was significant heterogeneity across the studies ($Q = 178.1, P < 0.001, I^2 = 78.1\%$). The summary RR was 0.89 (95% CI, 0.84-0.93) for low to moderate coffee consumption, with a significant heterogeneity between studies ($Q = 95.78, P < 0.001, I^2 = 61.4\%$). That for high consumption of coffee was 0.82 (95% CI, 0.74-0.89), also with a significant heterogeneity between studies ($Q = 114.71, P < 0.001, I^2 = 67.7\%$).

Various sources of heterogeneity likely exist due to international differences in coffee consumption (e.g., coffee type, serving size, or brewing method) in this analysis. To examine the magnitude of the combined RR in each stratum and its respective test of heterogeneity, we conducted subgroup analyses by gender, cancer sites, and geographic regions. The summary RR was 0.88 (95% CI, 0.78-0.98) for men and 0.87 (95% CI, 0.82-0.93) for women combining all studies. There was a significant heterogeneity for men ($Q = 118.27, P < 0.001, I^2 = 84.8\%$) and for women ($Q = 90.61, P < 0.001, I^2 = 75.7\%$).

When stratified by cancer sites, we noted that, coffee consumption was inversely associated with bladder (RR 0.83 (95% CI, 0.73-0.94)) (Figure 2), breast 0.94 (0.91-0.98) (Figure 3), buccal and pharyngeal 0.49 (0.29-0.70), colorectal 0.89 (0.80-0.97) (Figure 4), endometrial 0.74 (0.63-0.84) (Figure 5), esophageal 0.55 (0.37-0.74), hepatocellular 0.54 (0.46-0.61) (Figure 6), leukemic 0.64 (0.51-0.77), pancreatic 0.82 (0.69-0.95) (Figure 7), and prostate 0.79 (0.61-0.98) (Figure 8) cancers. There appeared to be no association with stomach, lung, non-melanoma, ovarian, or kidney cancer. The summary RR for an increment of 1 cup of coffee per day was 0.97 (95% CI, 0.96-0.98) for all studies combined. The pooled RR for various cancer sites and incremental estimates for 1 cup/day increment of coffee consumption and their heterogeneity are listed in Additional file 2: Table S2.

Associations were also similar in studies from North America, Europe, and the Asia-Pacific region. The RR was 0.92 (95% CI, 0.86-0.98) when considering 15 studies conducted in North America, 0.85 (95% CI, 0.72-0.98) for 13 studies from Europe and 0.82 (95% CI, 0.74-0.90) for 12 Asian studies. No significant differences by sex and cancer-site were found.

There was no indication of publication bias from either visualization of the funnel plot or Egger’s ($P = 0.793$) and Begg’s ($P = 0.981$) (Figure 9) tests. A sensitivity analysis, in which 1 study was removed at a time, was performed to evaluate the stability of the results. This analysis confirmed the stability of our results.

**Discussion**

Coffee can potentially impact the etiology of cancer of various sites along multiple pathways, ranging from carcinogenesis to cellular apoptosis. For most cancer sites, there is a significant amount of evidence showing no detrimental effect of consumption of up to 6 cups of coffee per day in relation to cancer occurrence. Through the meta-analysis of cohort studies, we found that compared with individuals who did not or seldom drink coffee per day, regular coffee drinkers had lower cancer occurrence, particularly for high drinkers. Overall, an increase in consumption of 1 cup of coffee per day was associated with a 3% reduced risk of cancers. The

**Results**

Using the predefined search strategy, we identified 59 publications, 40 prospective cohort studies, (Figure 1) including 2,179,126 participants and 34,177 incident cases of cancer with an average follow-up of 14.3 years, which were eligible for inclusion in the meta-analysis [15-73]. The characteristics of the included studies are summarized in Additional file: 1. Initial agreement between the two reviewers on whether a study was eligible for inclusion occurred in 207/221 manuscripts (93.7%; $k = 0.874$). Of the 40 cohorts included in the meta-analysis, 13 were conducted in Europe (Norway, Denmark, Sweden, France, Finland, and Netherlands), 15 in North America (Canada and the United States), and 12 in Asia (Japan and Singapore).

The estimated RRs of various cancer sites for coffee drinkers vs non/lowest drinkers was 0.87 (95% CI, 0.82-0.92). There was significant heterogeneity across the studies ($Q = 178.1, P < 0.001, I^2 = 78.1\%$). The summary RR was 0.89 (95% CI, 0.84-0.93) for low to moderate coffee consumption, with a significant heterogeneity between studies ($Q = 95.78, P < 0.001, I^2 = 61.4\%$). That for high consumption of coffee was 0.82 (95% CI, 0.74-0.89), also with a significant heterogeneity between studies ($Q = 114.71, P < 0.001, I^2 = 67.7\%$).

Various sources of heterogeneity likely exist due to international differences in coffee consumption (e.g., coffee type, serving size, or brewing method) in this analysis. To examine the magnitude of the combined RR in each stratum and its respective test of heterogeneity, we conducted subgroup analyses by gender, cancer sites, and geographic regions. The summary RR was 0.88 (95% CI, 0.78-0.98) for men and 0.87 (95% CI, 0.82-0.93) for women combining all studies. There was a significant heterogeneity for men ($Q = 118.27, P < 0.001, I^2 = 84.8\%$) and for women ($Q = 90.61, P < 0.001, I^2 = 75.7\%$).

When stratified by cancer sites, we noted that, coffee consumption was inversely associated with bladder (RR 0.83 (95% CI, 0.73-0.94)) (Figure 2), breast 0.94 (0.91-0.98) (Figure 3), buccal and pharyngeal 0.49 (0.29-0.70), colorectal 0.89 (0.80-0.97) (Figure 4), endometrial 0.74 (0.63-0.84) (Figure 5), esophageal 0.55 (0.37-0.74), hepatocellular 0.54 (0.46-0.61) (Figure 6), leukemic 0.64 (0.51-0.77), pancreatic 0.82 (0.69-0.95) (Figure 7), and prostate 0.79 (0.61-0.98) (Figure 8) cancers. There appeared to be no association with stomach, lung, non-melanoma, ovarian, or kidney cancer. The summary RR for an increment of 1 cup of coffee per day was 0.97 (95% CI, 0.96-0.98) for all studies combined. The pooled RR for various cancer sites and incremental estimates for 1 cup/day increment of coffee consumption and their heterogeneity are listed in Additional file 2: Table S2.

Associations were also similar in studies from North America, Europe, and the Asia-Pacific region. The RR was 0.92 (95% CI, 0.86-0.98) when considering 15 studies conducted in North America, 0.85 (95% CI, 0.72-0.98) for 13 studies from Europe and 0.82 (95% CI, 0.74-0.90) for 12 Asian studies. No significant differences by sex and cancer-site were found.

There was no indication of publication bias from either visualization of the funnel plot or Egger’s ($P = 0.793$) and Begg’s ($P = 0.981$) (Figure 9) tests. A sensitivity analysis, in which 1 study was removed at a time, was performed to evaluate the stability of the results. This analysis confirmed the stability of our results.

**Discussion**

Coffee can potentially impact the etiology of cancer of various sites along multiple pathways, ranging from carcinogenesis to cellular apoptosis. For most cancer sites, there is a significant amount of evidence showing no detrimental effect of consumption of up to 6 cups of coffee per day in relation to cancer occurrence. Through the meta-analysis of cohort studies, we found that compared with individuals who did not or seldom drink coffee per day, regular coffee drinkers had lower cancer occurrence, particularly for high drinkers. Overall, an increase in consumption of 1 cup of coffee per day was associated with a 3% reduced risk of cancers. The
evidence presented above suggests that coffee intake might reduce cancer occurrence in humans.

A significant amount of literature exists on relationships between coffee consumption and human cancer occurrence at 11 organ sites. It has been confirmed that coffee consumption is associated with a reduced risk of hepatocellular, kidney, and to a lesser extent, premenopausal breast and colorectal cancers, while it is unrelated to prostate, pancreas and ovary cancers. In subgroup analyses, we note that, for bladder, breast, buccal and pharyngeal, colorectal, endometrial, esophageal, hepatocellular, leukemic, pancreatic, and prostate cancers, there appears to be an inverse association.

Over the past two decades, many studies have been carried out after the early warning in the early 1980s that coffee consumption was related to pancreatic cancer risk. These investigations yield inconsistent results. Since the WCRF report, Luo et al. [59] studied the association between the drinking coffee and the risk of pancreatic cancer in a large population-based cohort study in Japan and concluded there was no increased risk of pancreatic cancer with coffee intake. A reduced risk was apparent among men who drank at least 3 cups of coffee per day. After a pooled analysis of 14 cohort studies, we found that coffee consumption had a significantly inverse association with the risk of pancreatic cancer.

Among investigations that have addressed the association between coffee consumption and the risk of kidney cancer, a pooled analysis of 13 cohort studies found that, coffee consumption was associated, but not significantly, with a lower risk of kidney cancer [74]. Among the participants in the Nurses’ Health Study and the Health Professionals Follow up Study, no association was seen between coffee intakes and risk of kidney cancer [63]. However, this conclusion is not confirmed by our results. There was a protective effect on men who drink coffee and for high coffee drinkers. Coffee
consumption may reduce kidney cancer risk because caffeine has a diuretic effect by blocking anti-diuretic hormone and antioxidants in coffee alleviate oxidative damage to DNA, proteins and other molecules. Moreover, coffee consumption may reduce the risk of kidney cancer by improving insulin sensitivity[75].

Colorectal cancer is one of the most common cancers worldwide. It has been suggested that coffee is a protective factor against colorectal cancer through its carcinogenic constituents, cafestol and kahweol and its ability to induce excretion of bile acids and neutral sterols into the colon[76]. Moreover, coffee might decrease colorectal cancer risk by increasing large bowel mobility in the rectosigmoid region, while caffeine has been shown to inhibit colon cancer cell growth[77]. A meta-analysis of prospective cohort studies on colorectal cancer and coffee consumption was completed and published in 2009[78]. The result of it showed no significant effect of coffee consumption on colorectal cancer risk. However, in our meta-analysis, 15 cohorts were identified from Japan, Norway, Finland, Singapore, Sweden, and the United States. We found that coffee consumption had an inverse association with the risk of colorectal cancer.

Preliminary results from the Nurses Health Study suggested a weak inverse association between caffeine intake and the risk of breast cancer[44]. A Norwegian cohort of 14,593 women who drank ≥5 cups of coffee per day experienced a statistically significant 50% decrease in breast cancer risk compared to those who drank ≤2 cups[79]. A meta-analysis of 9 cohort and 9 case-control studies found a borderline significant influence of highest coffee consumption on the risk of breast cancer. The results of our meta-analysis also confirmed the former conclusion and showed coffee drinking had an inverse association with breast cancer. We also observed a reduction of 26% in the risk of endometrial cancer among coffee drinkers, compared with nondrinkers, and of >30% among heavy coffee drinkers.

In addition, higher intake of caffeine and caffeine-containing beverages has been positively associated with sex hormone binding globulin and inversely associated with bioavailable testosterone[80]. These hormonal changes may favorably influence breast or endometrial cancer risk. Coffee consumption was also shown to be associated with increased ratio of plasma 2-hydroxyestrone to 16α-hydroxyestrone, a predictor of lower breast cancer risk[81].

A meta-analysis, including 6 case-control and 4 cohort studies reported a statistically significant 41% reduction in the hepatocellular cancer risk among coffee drinkers compared with never drinkers, with similar results from case-control and prospective studies [82]. Another meta-analysis of 4 cohort and 5 case-control studies found that an increased coffee consumption is associated with a reduced risk of hepatocellular cancer, both among individuals with and without a history of hepatocellular disease[83]. Our meta-analysis including 5 cohort studies also suggested a significant inverse relation between coffee intake and hepatocellular cancer.
Figure 5 Summary RRs of endometrial cancer for high coffee drinkers versus non/lowest drinkers from included studies. Squares represent study-specific relative risk estimates (size of the square reflects the study-specific statistical weight, that is, the inverse of the variance); horizontal lines represent 95% CIs; diamonds represent summary relative risk estimates with corresponding 95% CIs.

Figure 6 Summary RRs of hepatocellular cancer for high coffee drinkers versus non/lowest drinkers from included studies. Squares represent study-specific relative risk estimates (size of the square reflects the study-specific statistical weight, that is, the inverse of the variance); horizontal lines represent 95% CIs; diamonds represent summary relative risk estimates with corresponding 95% CIs.
A protective effect of coffee consumption on hepatocellular cancer is biologically plausible. Coffee contains large amounts of antioxidants, such as chlorogenic acids, and experimental studies in animals have demonstrated an inhibitory effect of coffee and chlorogenic acids on hepatocellular carcinogenesis[84]. In one animal study, caffeine levels of coffee extracts were inversely related to hepatocellular injury[85]. A population-based case-control study in the United States showed that higher intake of coffee, and especially caffeine, was associated with a lower prevalence of abnormal alanine aminotransferase activity[86]. In addition, some studies have reported an inverse association between coffee consumption and risk of hepatocellular cirrhosis, which is strongly related to HCC[87].

Coffee consumption and cancer of the urinary track was systematically reviewed in 2001[88]. We incorporated data on adjusted summary RRs from 9 cohort studies and found coffee to be inversely associated with bladder cancer in men, whereas the trend was not seen in women. The Lutheran Brotherhood Cohort study found coffee consumption unrelated to prostate cancer risk[60]. But we found that the summary RR of prostate cancer was 0.79 for coffee drinkers vs nondrinkers.

Some limitations of this meta-analysis should be acknowledged. First, as in all observational studies of diet and disease, the possibility of bias and confounding cannot be excluded (for some subjects may have modified their coffee drinking habit after the baseline assessment). However, cohort studies, which are less susceptible to bias because of the prospective design, also showed an inverse association between coffee consumption and risk of cancer, suggesting that the finding is not likely attributable to recall and selection bias. Individual studies may have failed to adjust for potential known or unknown confounders. Second, our results are likely to be affected
by some misclassification of coffee consumption. Coffee exposure is mostly assessed regarding the number of cups of coffee consumed daily, weekly or monthly. However, most of the studies included in our meta-analysis did not provide information on coffee type, serving size, or brewing method. Serving sizes and brewing methods for coffee can vary substantially within and between countries. The size of standard coffee cups is larger in the United States compared with that in Europe or Japan, and the difference in the strength of coffee brew may compensate for the different serving size between countries[89]. Third, we extracted the risk estimates that reflected the greatest degree of the control potential confounders, the results based on the adjustment for different confounders were probably different from those based on standardized adjustments. Finally, only published studies were included in our meta-analysis. Therefore, publication bias may have occurred although no publication bias was indicated from both visualization of the funnel plot and Egger’s test.
Conclusions

All in all, our meta-analysis including 40 prospective cohort studies confirmed that coffee drinking have no harmful effect. Instead, coffee consumption is inversely associated with the risk of bladder, breast, buccal cavity and pharynx, colorectum, endometrium, esophagus, hepatocellular, leukemia, pancreas, and prostate cancers.

Additional material

Additional file 1: Table S1 Summary characteristics of studies included in the meta-analysis.

Additional file 2: Table S2 The summary RR for various cancer sites or different geographic regions and incremental estimates for 1 cup/day increment of coffee consumption.

Acknowledgements

We thank the authors who kindly provided the data necessary for our meta-analysis.

Authors’ contributions

XY and JZ conceived the study. Data was acquired independently by XY and ZB. JD and JZ undertook data analysis and interpretation. JZ prepared the manuscript with contributions from all co-authors. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 12 November 2010 Accepted: 15 March 2011 Published: 15 March 2011

References

1. Food and Agricultural Organization. Food balance sheets. [http://www.fao.org/]
2. Huixley R, Lee CM, Barzi F, Timmermeister L, Czernichow S, Perkovic V, Grobbee DE, Batty D, Woodward M: Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med 2009, 169(22):2053-2063.
3. Sääksjärvi K, Kniet P, Rissanen H, Laaksosen MA, Reunanen A, Mannisto S: Prospective study of coffee consumption and risk of Parkinson’s disease. Eur J Clin Nutr 2008, 62(7):908-915.
4. Modi AA, Feld JJ, Park Y, Kliener DE, Everhart JE, Liang TJ, Hoofnagle JH: Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010, 51(1):201-209.
5. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. American Institute for Cancer Research, Washington, DC, 2007.
6. Huber WW, Scharf G, Nagel G, Prustomersky S, Schulte-Hermann R, Kaina B: Coffee and its chemopreventive components Kahweol and Cafestol increase the activity of O6-methylguanine-DNA methyltransferase in rat liver-comparison with phase II xenobiotic metabolism. Mutat Res 2003, 522:57-68.
7. Cavin C, Marin-Kuan M, Langouët S, Bezençon C, Guignard G, Verguet C, Piguet D, Holzhauer D, Comar R, Schilter B: Induction of Nrf2-mediated cellular defenses and alteration of phase I activities as mechanisms of chemoprotective effects of coffee in the liver. Food Chem Toxicol 2008, 46(4):1239-1248.
8. Ramos S: Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 2008, 52:507-526.
9. Vuic EA, Brown CJ, Lam WL: Epigenetics of cancer progression. Pharmacogenomics 2008, 9:215-234.
10. Shearer J, Farah A, de Paulis T, Brady DP, Pencek RR, Graham TE, Wasserman DH: Quinides of roasted coffee enhance insulin action in conscious rats. J Nutr 2003, 133(11):3529-3532.
11. Renehan AG, Roberts DL, Dve C: Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 2008, 114:1-83.
12. Stroup DF, Berlin JA, Morton SC, Olin K, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
13. Greenland S, Longnecker MP: Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992, 135:1301-1309.
14. Orsini N, Bellocco R, Greenland S: Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006, 6:40-57.
15. Inoue M, Yoshimi I, Sobue T, Tsugane S, JPHC Study Group: Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005, 97(4):293-300.
16. Shimazu T, Tsuono Y, Kuriyama S, Ohmori K, Koizumi Y, Nishino Y, Shibuuya D, Tsuji I: Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005, 116(1):150-154.
17. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, Sakata R, Fujita Y, Ichikawa S, Iwai N, Tamakoshi A, JACC Study Group: Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005, 93(5):607-610.
18. Hu G, Tuomilehto J, Pukkala E, Hakulinen T, Antikainen R, Vartiainen E, Joussilvã P: Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 2008, 48(1):129-136.
19. Shimazu T, Inoue M, Sasazuki S, Iwasaki M, Kurahashi N, Yamaji T, Tsugane S, JPHC Study Group Members of the Japan Public Health Center-Based Prospective Study: Coffee consumption and risk of endometrial cancer: a prospective study in Japan. Int J Cancer 2008, 123(10):2404-2410.
20. Friefe ER, Orsini N, Mantzoros CS, Wolk A: Coffee drinking and risk of endometrial cancer-A population-based cohort study. Int J Cancer 2009, 125:2413-2417.
21. Larsson SC, Wolk A: Coffee consumption is not associated with ovarian cancer incidence. Cancer Epidemiol Biomarkers Prev 2005, 14(9):2273-2274.
22. Silversa SA, Jain M, Howe GR, Miller AB, Rohan TE: Intake of coffee and tea and risk of ovarian cancer: a prospective cohort study. Nutr Cancer 2007, 58(1):22-27.
23. Stevens J, Schouten LJ, Verhage BA, Goldbohm RA, van den Brandt PA: Tea and coffee drinking and ovarian cancer risk: results from the Netherlands Cohort Study and a meta-analysis. Br J Cancer 2007, 97(9):1291-1294.
24. Twohroyer SS, Gertig DM, Gales MA, Hecht JL, Hankinson SE: Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 2008, 112(5):1169-1177.
25. vanloon AJ, Goldbohm RA, van den Brandt PA: Socioeconomic status and stomach cancer incidence in men: results from The Netherlands Cohort Study. Epidemiol Community Health 1998, 52:166-171.
26. Galanis DJ, Kolonel LN, Lee J, Nomura A: Intakes of selected foods and beverages and the incidence of gastric cancer among the Japanese residents of Hawaii: a prospective study. International Journal of Epidemiology 1998, 27:173-180.
27. Tsuono Y, Nishino Y, Komatsu S, Hiseh CC, Kanemura S, Tsuji I, Nakatsuka H, Fukao A, Sato H, Hisamichi S: Green tea and the risk of gastric cancer in Japan. N Engl J Med 2001, 344(9):632-639.
28. Larsson SC, Giovannucci E, Wolk A: Coffee consumption and stomach cancer risk in a cohort of Swedish women. Int J Cancer 2006, 119(9):2186-2189.
29. Wu AH, Paganini-Hill A, Ross RK, Henderson BE: Alcohol, physical activity and other risk factors for colorectal cancer: A prospective study. Br J Cancer 1987, 55:687-694.
30. Katsay AL, Armstrong MA, Friedman GD, Hatt RA: The relations of alcoholic beverage use to colon and rectal cancer. Am J Epidemiol 1988, 128(5):1007-1015.
31. Hartman TJ, Tangrea JA, Pietinen P, Malila N, Virtanen M, Taylor PR, Albanes D: Tea and coffee consumption and risk of colon and rectal cancer in middle-aged Finnish men. Nutr Cancer 1998, 31(1):41-48.
32. Terry P, Bergkvist L, Holmbom L, Wolk A. Coffee consumption and risk of colorectal cancer in a population based prospective cohort of Swedish women. Gut 2001; 49(1):87-90.
33. Michels KB, Willett WC, Fuchs CS, Giovannucci E. Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer. Natl Cancer Inst 2005, 97(4):282-292.
34. Larsson SC, Bergkvist L, Giovannucci E, Wolk A. Coffee consumption and incidence of colorectal cancer in two prospective cohort studies of Swedish women and men. Am J Epidemiol 2006, 163(7):638-644.
35. Oba S, Shimizu N, Nagata C, Shimizu H, Karmetari M, Takeyama N, Ohnuma T, Matsuishi S. The relationship between the consumption of meat, fat, and coffee and the risk of colon cancer: a prospective study in Japan. Cancer Lett 2006, 244(2):260-267.
36. Naganuma T, Kuryama S, Akhter M, Kikizaki M, Nakaya N, Matsuda-Ohmori K, Shimazu T, Fukao A, Tsuji I. Coffee consumption and the risk of colorectal cancer: a prospective cohort study in Japan. Int J Cancer 2007, 120(7):1542-1547.
37. Lee KL, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S, JPHC Study Group. Coffee consumption and risk of smoking, alcohol consumption, and dietary factors for pancreatic cancer (United States). Cancer Causes Control 1993, 4(5):477-482.
38. Shibata A, Mack TM, Paganini-Hill A, Ross RK, Henderson BE. A prospective study of pancreatic cancer in the elderly. Int J Cancer 1994, 58(1):46-49.
39. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Coffee and alcohol consumption and the risk of pancreatic cancer in two prospective United States cohorts. Cancer Epidemiol Biomarkers Prev 2001, 10(5):429-437.
40. Isaksson B, Jonsson F, Pedersen NL, Larsson J, Feychting M, Pernert J. Lifestyle factors and pancreatic cancer risk: a cohort study from the Swedish Twin Registry. Int J Cancer 2002, 98(3):480-482.
41. Lin Y, Tamakoshi A, Kawamura T, Inaba Y, Kikuchi S, Motohashi Y, Kuroawa M, Ohno Y. Risk of pancreatic cancer in relation to alcohol drinking, coffee consumption and medical history: findings from the Japan collaborative cohort study for evaluation of cancer risk. Int J Cancer 2002, 99(5):742-746.
42. Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, Vintano J, Alabanes D. Prospective study of diet and pancreatic cancer in male smokers. Am J Epidemiol 2002, 155(9):783-792.
43. Luo J, Inoue M, Iwasaki M, Sasazuki S, Otani T, Ye W, Tsugane S, JPHC Study Group. Green tea and coffee intake and risk of pancreatic cancer in a large-scale, population-based cohort study in Japan (JPHC study). Eur J Cancer Prev 2007, 16(6):542-546.
44. Hising AW, McLaughlin JK, Schuman LM, Bollie E, Gridley G, Wacholder S, Chen HT, Blot WJ. Diet, tobacco use, and fat prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res 1990, 50(21):6836-6840.
45. Ellison LF. Tea and other beverage consumption and prostate cancer risk: a Canadian retrospective cohort study. Eur J Cancer Prev 2000, 9(2):125-130.
46. Washio M, Morii M, Sakauchi F, Watanabe Y, Ozasa K, Hayashi K, MiKi T, Nakao M, Mikami K, Ito Y, Waki K, Tamakoshi A, JACC Study Group. Risk factors for kidney cancer in a Japanese population: findings from the JACC Study. J Epidemiol 2005, 15(Suppl 2):S203-211.
47. Lee JE, Giovannucci E, Smith-Warner SA, Spiegelman D, Willett WC, Cuthan GC. Total fluid intake and use of individual beverages and risk of renal cell cancer in two large cohorts. Cancer Epidemiol Biomarkers Prev 2006, 15(6):1204-1211.
48. Abel EL, Hendrix SD, McKeelley SG, Johnson KC, Rosenberg CA, Mossavar-Rahmani Y, Vitols M, Kruger M. Daily coffee consumption and prevalence of nonmelanoma skin cancer in Caucasian women. Eur J Cancer Prev 2007, 16(3):446-452.
49. Veierød MB, Thelle DS, Laake P. Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer 1997, 71(4):600-604.
50. Ma A, Park Y, Mayne ST, Wang R, Sinha R, Hollenbeck AR, Schatzkin A, Cross AJ. Diet, lifestyle, and acute myeloid leukemia in the NIH-AARP cohort. Am J Epidemiol 2010, 171(12):312-322.
51. Snowdon DA, Phillips RL. Coffee consumption and risk of fatal cancers. Am J Public Health 1984, 74(8):820-823.
52. Jacobsen BK, Bollie E, Külle G, Heuch H. Coffee drinking, mortality, and cancer incidence: results from a Norwegian prospective study. J Natl Cancer Inst 1996, 76(5):823-831.
53. Nomura A, Heilbrun LK, Stemmermann GN. Prospective Study of coffee consumption and the risk of cancer. J Natl Cancer Inst 1986, 76(5):587-590.
54. Stensvold I, Jacobsen BK. Coffee and cancer: a prospective study of 43,000 Norwegian men and women. Cancer Causes Control 1994, 5(1):401-408.
55. Kusunoki M, Goto R, Kobayashi K, Suzumura S, Nagata Y, Sonoda T, Sakauchi F, Washio M, Morii M. Dietary habits and cancer mortality among middle aged and older Japanese living in hokkaido, japan by cancer site and sex. Asian Pacific J Cancer Prev 2004, 5:58-65.
56. Naganuma T, Kuryama S, Kikizaki M, Sone T, Nakaya N, Oohori-Matsuda K, Nishino Y, Fukao A, Tsuji I. Coffee consumption and the risk of oral, pharyngeal, and esophageal cancers in Japan: the Miyagi Cohort Study. Am J Epidemiol 2000, 16(12):1423-1432.
57. Zheng W, Doyle TJ, Kushi LH, Sellers TA, Hong CP, Folsom AR. Tea consumption and cancer incidence in a prospective cohort study of postmenopausal women. Am J Epidemiol 1996, 144(2):175-182.
58. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Bernstein L, van den Brandt PA, Buring JE, Cho E, English D, Folsom AR, Freudenberg JL.
Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies. *Int J Cancer* 2007, 121(10):2246-2253.

75. Arnlöv J, Vessby B, Risérus U: Coffee consumption and insulin sensitivity. *JAMA* 2004, 291(10):1199-1201.

76. Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, Schilter B: Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. *Food Chem Toxicol* 2002, 40:1155-1163.

77. Merighi S, Benini A, Mirandola P, Gesi P, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, Borea PA: Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. *Mol Pharmacol* 2007, 72(2):395-406.

78. Je Y, Liu W, Giovannucci E: Coffee consumption and risk of colorectal cancer: a systematic review and meta-analysis of prospective cohort studies. *Int J Cancer* 2009, 124(7):1662-1668.

79. Vatten LJ, Solvoll K, Løken EB: Coffee consumption and the risk of breast cancer. A prospective study of 14,593 Norwegian women. *Br J Cancer* 1990, 62(2):267-270.

80. Niagata C, Kabuto M, Shimizu H: Association of coffee, green tea, and caffeine intakes with serum concentrations of estradiol and sex hormone-binding globulin in premenopausal Japanese women. *Nutr Cancer* 1998, 30:21-24.

81. Jernstrom H, Klug TL, Sepkovic DW, Bradlow HL, Narod SA: Predictors of the plasma ratio of 2-hydroxyestrone to 16-alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups. *Carcinogenesis* 2003, 24:991-1002.

82. Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, Franceschi S, La Vecchia C: Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. *Hepatology* 2007, 46(2):430-435.

83. Larsson SC, Wolk A: Coffee consumption and risk of liver cancer: a meta-analysis. *Gastroenterology* 2007, 132(5):1740-1745.

84. Tanaka T, Nishikawa A, Shima H, Sugie S, Shinoda T, Yoshimi N, Iwata H, Mori H: Inhibitory effects of chlorogenic acid, reserpine, polypropenoid acid (E-5166), or coffee on hepatocarcinogenesis in rats and hamsters. *Basic Life Sci* 1990, 52:429-440.

85. He P, Noda Y, Sugiyama K: Suppressive effect of coffee on lipopolysaccharide-induced hepatitis in D-galactosamine-sensitized rats. *Biosci Biotechnol Biochem* 2001, 65:1924-1927.

86. Ruhl CE, Everhart JE: Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. *Gastroenterology* 2005, 128:24-32.

87. La Vecchia C, Negri E, Cavaliere O’Ror L, Franceschi S: Liver cirrhosis and the risk of primary liver cancer. *Eur J Cancer Prev* 1998, 7:315-320.

88. Zeegers MP, Tan FE, Goldbohm RA, van den Brandt PA: Are coffee and tea consumption associated with urinary tract cancer risk? A systematic review and meta-analysis. *Int J Epidemiol* 2001, 30(2):353-362.

89. Bracken MB, Tisch E, Grosso L, Hellenbrand K, Belanger K, Leaderer BP: Heterogeneity in assessing self-reports of caffeine exposure: implications for studies of health effects. *Epidemiology* 2002, 13:165-171.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/11/96/prepub

doi:10.1186/1471-2407-11-96
Cite this article as: Yu et al.: Coffee consumption and risk of cancers: a meta-analysis of cohort studies. *BMC Cancer* 2011 11:96.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit